On the other hand, circulating FABP4 has been proposed as an independent predictor of CV mortality in the general population [57] and in patients with end-stage renal disease [52], peripheral arterial disease [42], coronary heart disease [52], stable angina undergoing percutaneous coronary intervention [54], ischemic stroke [49] and T2D [40,41,55]. Here, FABP4 is linked to type 2 diabetes mellitus.